Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy
- PMID: 12025835
- DOI: 10.1016/s1072-7515(02)01128-6
Transanal excision of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy
Abstract
Background: Our institution has previously demonstrated a survival advantage conferred by preoperative neoadjuvant therapy for locally advanced rectal cancers. We now report our results using transanal excision as definitive surgical therapy in a selected group of patients who experienced significant downstaging of T3 rectal cancers after neoadjuvant therapy.
Study design: Seventy-four patients diagnosed with locally advanced (T3) rectal cancers were treated with neoadjuvant chemoradiotherapy. After neoadjuvant therapy, 11 (14.9%) patients who had significant downstaging of their tumors were selected to undergo transanal excision of their residual rectal cancers. Intraoperative cryostat evaluation was used to confirm negative margin status, and all patients were subsequently followed with routine endoscopy, transrectal ultrasonography, and digital rectal examinations.
Results: Tumors were located between 1 cm and 7 cm from the anal verge (mean 4.3 +/- 0.6 cm), and were located in lateral, anterior, and posterior positions. Mean followup was 55.2 +/- 8.9 months (median 47.9 months). Imaging studies using CT, MRI, transrectal ultrasonography, or combination demonstrated suspicious lymph nodes in three patients. After neoadjuvant therapy, these lymph nodes were no longer demonstrated in two patients. There were no local recurrences, nodal metastases, or operative mortalities. One patient (9%) developed distant metastases (pulmonary nodules), and remains alive 30 months after transanal excision. One patient (9%) experienced sphincter laxity, which was successfully repaired, and is now asymptomatic. One patient (9%) developed postoperative urgency that resolved spontaneously.
Conclusions: In patients who have initial bulky (T3) lesions, and experience significant downstaging after neoadjuvant chemoradiotherapy, transanal excision appears to be a safe and effective treatment, preserving sphincter function and avoiding laparotomy.
Similar articles
-
Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.Dis Colon Rectum. 2013 Jan;56(1):6-13. doi: 10.1097/DCR.0b013e318273f56f. Dis Colon Rectum. 2013. PMID: 23222274
-
Laparoscopic transanal abdominal transanal resection with sphincter preservation for rectal cancer in the distal 3 cm of the rectum after neoadjuvant therapy.Surg Endosc. 2010 Nov;24(11):2700-7. doi: 10.1007/s00464-010-1028-8. Epub 2010 Apr 23. Surg Endosc. 2010. PMID: 20414681
-
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.Lancet Oncol. 2015 Nov;16(15):1537-1546. doi: 10.1016/S1470-2045(15)00215-6. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26474521 Free PMC article. Clinical Trial.
-
Transanal endoscopic microsurgery for rectal cancer: T1 and beyond? An evidence-based review.Surg Endosc. 2016 Nov;30(11):4841-4852. doi: 10.1007/s00464-016-4818-9. Epub 2016 Feb 22. Surg Endosc. 2016. PMID: 26902614 Review.
-
Paradigm-shifting new evidence for treatment of rectal cancer.J Gastrointest Surg. 2014 Feb;18(2):391-7. doi: 10.1007/s11605-013-2297-z. Epub 2013 Jul 26. J Gastrointest Surg. 2014. PMID: 23888373 Review.
Cited by
-
Neoadjuvant therapy followed by local excision and two-stage total mesorectal excision: a new strategy for sphincter preservation in locally advanced ultra-low rectal cancer.Gastroenterol Rep (Oxf). 2014 Feb;2(1):37-43. doi: 10.1093/gastro/got040. Epub 2014 Jan 21. Gastroenterol Rep (Oxf). 2014. PMID: 24760235 Free PMC article.
-
Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer.Ann Surg Oncol. 2010 Feb;17(2):441-7. doi: 10.1245/s10434-009-0735-7. Epub 2009 Oct 22. Ann Surg Oncol. 2010. PMID: 19847569 Free PMC article.
-
Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.World J Gastroenterol. 2013 Aug 28;19(32):5227-37. doi: 10.3748/wjg.v19.i32.5227. World J Gastroenterol. 2013. PMID: 23983425 Free PMC article. Review.
-
Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma.J Gastrointest Surg. 2004 Jan;8(1):56-62; discussion 62-3. doi: 10.1016/j.gassur.2003.09.019. J Gastrointest Surg. 2004. PMID: 14746836
-
Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies.Ann Surg Oncol. 2011 Dec;18(13):3686-93. doi: 10.1245/s10434-011-1822-0. Epub 2011 Jun 21. Ann Surg Oncol. 2011. PMID: 21691880 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources